Clinical trials: Brain Structure
Stroke, Atrial Fibrillation
GLORIA-AF Registry Program - Second and Third Phases
In this part of the Registry Program patients with non-valvular atrial fibrillation (AF) at risk for stroke are enrolled to characterize the target population and to collect real world data on important outcome events.
- Trial name
- NCT01468701
- Where
- 666 sites in United States, Argentina and 19 more
- Volunteers
- 37,235 people
- Sponsor
- Boehringer Ingelheim
Multiple System Atrophy
Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)
To test the clinical effect of rasagiline on subjects with MSA of the parkinsonian subtype.
- Trial name
- NCT00977665
- Testing
- rasagiline mesylate
- Where
- 47 sites in United States, Austria and 10 more
- Volunteers
- 174 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Migraine With Aura
Tonabersat in the Prophylaxis of Migraine With Aura
Overall trial objectives: 1. Can treatment with tonabersat reduce the number of days with aura and/or migraine headache in patients with migraine with aura 2.
- Trial name
- NCT00332007
- Testing
- Tonabersat
- Where
- Denmark
- Volunteers
- 39 people
- Sponsor
- Minster Research Ltd
Memory Dysfunction, Mood Disorders
To Access the Effect of Brain Pill™ on Working Memory Capacity and Mood Behaviour.
Brain Pill™ is a mental health enhancing and successfully marketed dietary supplement.
- Trial name
- NCT03198936
- Testing
- Cognizin® SynapsaTM
- Where
- India
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Ruptured Cerebral Aneurysm
A Medical Device to Treat Wide-Neck Brain Aneurysms
The study aims to evaluate the safety and probable benefit of a medical device to treat wide-neck ruptured brain aneurysms.
- Trial name
- TORNADO-US (NCT05550571)
- Testing
- Nautilus Intrasaccular Bridging System
- Where
- 5 sites in United States, Bulgaria
- Volunteers
- 45 people
- Sponsor
- EndoStream Medical
Ischemic Stroke; Ischemic Attack, Transient
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
- Trial name
- LIBREXIA-STROK (NCT05702034)
- Testing
- Milvexian
- Where
- 880 sites in United States, Argentina and 45 more
- Volunteers
- 12,523 people
- Sponsor
- Janssen Research & Development, LLC
Friedreich Ataxia
A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old
In this study, researchers will learn more about BIIB141, also known as omaveloxolone or SKYCLARYS®. This drug has been approved, or made available for doctors to prescribe, for people with Friedrich's Ataxia (FA) who are at…
- Trial name
- BOLD (NCT06054893)
- Testing
- Omaveloxolone
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Biogen
Stroke
Brain Vital Signs M-Score: Point-of-care Monitoring for Motor Recovery After Stroke
The purpose of this study is to investigate brain signals relating to motor function, using electroencephalography (EEG) technology. The aims of the study can be separated into 3 specific study objectives: 1.
- Trial name
- NCT03858699
- Testing
- Recording of electroencephalographic (EEG) data
- Where
- Canada
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- HealthTech Connex Inc.
Growth Hormone Disorder, Adult Growth Hormone Deficiency
Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)
This study is conducted in the United States of America (USA). The aim of the study is to assess the minimal important difference (MID) of the TRIM-AGHD.
- Trial name
- NCT02005198
- Testing
- No treatment given
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Novo Nordisk A/S
Parkinson's Disease
An Evaluation of the Pharmacokinetics and Pharmacodynamics of AP09004 in Patients With Parkinson's Disease
The purpose of this study is to evaluate blood level profiles of multiple oral doses of AP09004 vs. active control and to determine its safety and efficacy in Parkinson's patients.
- Trial name
- NCT00918177
- Testing
- AP09004, Carbidopa/Levodopa, immediate release
- Where
- 7 sites in Israel
- Volunteers
- 72 people
- Sponsor
- Intec Pharma Ltd.
Stroke, Acute
A Phase 4 Clinical Study to Investigate the Efficacy and Safety of Naloxone HCI IV in Patients With Stroke
This clinical trial was planned for the purpose to re-evaluate the safety and efficacy of naloxone hydrochloride in ischemic cerebral nerve disorders caused by stroke and cerebral hemorrhage.
- Trial name
- NCT05301712
- Testing
- Naloxone hydrochloride 5.0mg/5ml, Sodium Chloride 45mg/5ml
- Where
- South Korea
- Volunteers
- 446 people
- Sponsor
- Samjin Pharmaceutical Co., Ltd.
Metachromatic Leukodystrophy (MLD)
Multicenter Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy (MLD)
The purpose of this study is to determine the safety of ascending doses of HGT-1110 administered by intrathecal (IT) injection for 38 weeks (20 injections) in children with metachromatic leukodystrophy (MLD).
- Trial name
- IDEAMLD (NCT01510028)
- Testing
- Recombinant human arylsulfatase A
- Where
- 5 sites in Australia, Denmark and 3 more
- Volunteers
- 24 people
- Sponsor
- Shire
Alzheimer's Disease
A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI
To purpose of this study is to estimate the effect of donepezil on Neuropsychological Testing (NPT) and brain Proton Magnetic Resonance Spectroscopy.
- Trial name
- NCT00483028
- Testing
- donezepil (Aricept)
- Where
- 2 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Pfizer
Alzheimer's Disease
18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease
This follow-up study continues to observe patients who have completed the phase 1 trial of AADvac1, for another 18 months. Long-term safety and behavior of the immune response to AADvac1 over time are the main points of interest.
- Trial name
- FUNDAMANT (NCT02031198)
- Testing
- AADvac1
- Where
- 4 sites in Austria
- Volunteers
- 25 people
- Sponsor
- Axon Neuroscience SE
Alzheimer's Disease
Effects of ONO-2506PO in Patients With Alzheimer's Disease
The purpose of this study is to establish the presence of an effect of treatment with ONO-2506PO in patients with Alzheimer's Disease, based upon cognitive and global scales.
- Trial name
- NCT00083421
- Testing
- ONO-2506PO
- Where
- 87 sites in United States, Canada
- Volunteers
- 647 people
- Sponsor
- Ono Pharma USA Inc
Infantile Spasms
Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy
The sponsor is developing a new paediatric formulation of vigabatrin to better adjust the dose to body weight and to limit waste of unused drug.
- Trial name
- SoluWest (NCT02220114)
- Testing
- Vigabatrin: Vigabatrin new ST formulation then Sabril®
- Where
- 12 sites in France
- Volunteers
- 38 people
- Sponsor
- Orphelia Pharma
Alzheimer's Disease
Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease to evaluate the safety and tolerability of oral CT1812…
- Trial name
- NCT02907567
- Testing
- CT1812
- Where
- 4 sites in Australia
- Volunteers
- 19 people
- Sponsor
- Cognition Therapeutics
Parkinson's Disease
A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease
The objective of this trial was to assess subject preference for PARCOPA, carbidopa/levodopa Orally Disintegrating Tablets (ODT), compared with conventional carbidopa/levodopa tablets, in subjects with stable Parkinson's disease.
- Trial name
- NCT00139867
- Testing
- PARCOPA
- Where
- United States
- Sponsor
- UCB Pharma
Acquired Bleeding Disorder, Trauma
Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury
This study is conducted in North America. The purpose of this study is to evaluate the occurrence and severity of bleeding in brain injury and to identify important safety issues following traumatic brain injury.
- Trial name
- NCT00124293
- Testing
- activated recombinant human factor VII
- Where
- 2 sites in United States, Canada
- Volunteers
- 63 people
- Sponsor
- Novo Nordisk A/S
Subdural Hematoma
MMA Embolization With NeoCast for Subacute and Chronic Subdural Hematoma
The purpose of this study is to evaluate the safety and efficacy of embolization of the middle meningeal artery (MMA) using the NeoCast Embolic System for treatment of symptomatic subacute or chronic subdural hematoma (SDH)…
- Trial name
- RADIANT (NCT07541404)
- Testing
- NeoCast Embolic System, Onyx LES, an FDA-Approved Commercial Liquid Embolic
- Where
- 2 sites in United States
- Volunteers
- 360 people
- Sponsor
- Arsenal Medical, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.